<DOC>
	<DOCNO>NCT00574912</DOCNO>
	<brief_summary>The study determine dose response relationship insulin glargine type 2 diabetes 24-hour period measure difference glucose production among differ dos glargine . Hypothesis : Differing dos insulin glargine 24-hour period type 2 diabetes show differ effect endogenous glucose production , glucose disposal carbohydrate lipid flux .</brief_summary>
	<brief_title>Characteristics Glargine Type 2 Diabetics</brief_title>
	<detailed_description>The incidence type 2 DM increase worldwide alarm rate . Unfortunately , number individual glycemic control American Diabetes Association goal 7 % drop . In fact , number patient important cardiometabolic risk factor glucose , lipid blood pressure goal 7 % . One reason lack metabolic control type 2 DM continue relative underutilization insulin . Diabetes insulin deficient state require appropriate physiologic replacement insulin . Physiologic replacement insulin require basal component restrain overnight endogenous glucose production , lipolysis proteolysis . The component involve prandial insulin regulate post prandial glucose level . Recently , insulin glargine introduce once-a-day peakless basal insulin . This form basal insulin reproduces normal constitutive physiologic release insulin pancreas . Insulin glargine represent breakthrough treatment previous available `` basal insulin '' either produce peak activity ( disadvantageous result hypoglycemia ) last 24 hrs result post absorbative hyperglycemia . Despite undoubted advantage insulin glargine , remain lack information regard aspect glargine action . The study objective : 1 ) determine pharmacokinetic pharmacodynamic dose response relationship insulin glargine Type 2 DM ; 2 ) partition dose response relationship insulin glargine endogenous glucose production glucose uptake Type 2 DM ; 3 ) determine pharmacokinetic pharmacodynamics insulin glargine consistent wide range dos .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>12 adult ( male female ) type 2 diabetes least six ( 6 ) month . May use oral agent ( SUs , metformin , acarbose glitinides ) without insulin . HgbA1c 7 12 % Age 1870 year BMI 2740 kg/mÂ² Any past present clinically relevant abnormality , medical condition , circumstance making subject unsuitable participation study Evidence hepatic , renal cardiac failure Abnormal result follow screen test Pregnant lactate female female childbearing potential unwilling abstain sexual intercourse use reliable , medically accept method contraception Currently use TZDs History alcoholism drug abuse within 12 month study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Insulin Glargine</keyword>
	<keyword>Endogenous Glucose Production</keyword>
</DOC>